ArticleBMC pregnancy and childbirth2026
Clinical features and maternal-fetal outcomes of patients with first-onset acute leukemia during pregnancy: a retrospective study from pregnancy hematological disease referral center.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to characterize the clinical features, maternal-fetal outcomes, and prognostic factors of pregnant patients with first-onset acute leukemia (AL) at a specialized referral center in China.
methodsA retrospective descriptive study was conducted on 53 pregnant patients diagnosed with de novo AL and treated at Peking University People’s Hospital between January 2010 and January 2024. Clinical data, including maternal baseline characteristics, treatment protocols, pregnancy outcomes, and long-term maternal/neonatal follow-up results, were collected and analyzed. Survival outcomes were estimated using Kaplan-Meier curves, and prognostic factors for maternal mortality were identified via Cox regression analysis.
resultsOf the 53 patients, 40 (75.5%) had acute myeloid leukemia (AML) and 13 (24.5%) had acute lymphoblastic leukemia (ALL); AL onset occurred in the first (n = 12, 22.6%), second (n = 28, 52.8%), and third (n = 13, 24.6%) trimesters. The most common initial symptoms were oral manifestations (34.0%, e.g., gingival bleeding/hyperplasia), while thrombocytopenia (94.3%) and anemia (86.8%) were the most prevalent peripheral blood abnormalities. 23 (43.4%) patients reached the peripartum period (≥ 28 weeks), with 56.5% preterm births and 13.0% fetal growth restriction (FGR). Gestational age at AL onset was the only factor significantly associated with peripartum progression (OR = 1.642, p < 0.001). Seven patients received antenatal induction chemotherapy, all achieving live births. Long-term follow-up (median: 4.4 years) of 17/22 live-born children showed no growth restriction or neurodevelopmental delays. The 5-year overall survival (OS) and disease-free survival (DFS) rates for mothers were 50.9% and 41.5%, respectively. Cox regression identified disseminated intravascular coagulation (DIC, HR = 5.274, p = 0.022) and leukocytosis (HR = 5.009, p = 0.025) as independent risk factors for maternal mortality; chemotherapy delay (> 30 days) was associated with lower complete remission (CR) rates (66.7% vs. 87.1%) and higher mortality (50% vs. 26.7%).
conclusionUnexplained thrombocytopenia or oral manifestations are key early indicators for targeted AL screening in pregnant patients. Gestational age at AL onset was the only factor significantly associated with peripartum progression. Disseminated intravascular coagulation and leukocytosis were independent risk factors for maternal mortality. Among 17 live-born children with a median follow-up of 4.4 years, no growth restriction or neurodevelopmental delays were observed, including 6 infants exposed to antenatal ATRA-based chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.